Sphingosine-1-phosphate (S1P) is a cellular signalling lipid generated by sphingosine kinase-1 (SPHK1). The aim of the study was to investigate whether the activated coagulation factor-X (FXa) regulates SPHK1 transcription and the formation of S1P and subsequent mitogenesis and migration of human vascular smooth muscle cells (SMC).
Introduction
The activated clotting factor-X (FXa) is of key importance in the coagulation cascade. After vascular injury, FX is activated on the surface of tissue factor (TF)-bearing cells, such as smooth muscle cells (SMC), which ultimately leads to the activation of thrombin and thrombus formation. 1 Besides its function in blood coagulation, FXa can stimulate vascular SMC proliferation and migration and alter the composition of the extracellular matrix. 2 -5 These are key events in the development of atherosclerosis and restenosis after vascular injury. 6 -8 Thus, haemostatic factors such as thrombin and FXa are thought to directly contribute to the pathogenesis of vascular diseases. 9 -11 However, the precise role of FXa in the development and progression of atherosclerosis has not been evaluated to date. Direct cellular effects of thrombin and FXa on SMC are mediated by protease-activated receptors (PAR-1 to PAR-4), a subgroup of the G-protein-coupled receptors (GPCRs). Thrombin acts through PAR-1, PAR-3, and PAR-4, while FXa can activate PAR-1 and PAR-2, which does not respond to thrombin. 9, 10 Recent insights into the role of PARs for platelet activation and vascular biology have led to considerable interest in PARs as therapeutic targets for the prevention of atherothrombosis and the development of novel anti-atherosclerotic drugs. 12, 13 An important regulator of cellular functions is the signalling lipid sphingosine-1-phosphate (S1P).
14 S1P is generated by sphingosine kinase (SPHK), of which two isoforms-SPHK1 and SPHK2-have been described. 15 S1P is a ligand for a family of five GPCRs, the S1P receptors S1P 1 -5 . 14, 16 Via activation of these receptors, S1P regulates not only endothelial permeability but also diverse cellular functions, including cell proliferation, differentiation, migration, organization of the cytoskeleton, angiogenesis, and inflammatory reactions. 14, 16, 17 Recently, S1P has also been suggested to control atherosclerotic lesion formation via controlling leucocyte recruitment and modifying smooth muscle cell function. 18 In addition to extracellular S1P effects, some studies describe intracellular second messenger-like functions for S1P, e.g. for cellular proliferation, 19 calcium homeostasis, 20 and for the suppression of apoptosis. 15, 21 The present study addresses the question whether the activated coagulation factor-X can interact with the vascular S1P system, and whether this may be relevant for atherosclerotic plaque development. Our data suggest that FXa increases the expression of SPHK-1 and S1P formation in human vascular SMC. This may play an important role in key processes leading to atherosclerotic plaque development independent of its role as a catalyst of thrombin formation in the haemostatic prothrombin complex.
Methods
Please see Supplementary material online for more detailed Methods.
Materials
Monoclonal antibodies against SPHK1 (clone 1D6) were from Abnova (Heidelberg, Germany) and against FX/FXa (ab61361) from Abcam (Cambridge, UK). Goat anti-human TF antibody (4501) was from American Diagnostica, a-smooth muscle actin (clone ab5694) and smoothelin (clone ab8969) were from Abcam. Purified human FX, Fxa, and FVII were from Kordia (Leiden, the Netherlands). Activating peptides for the protease-activated receptors (PAR-APs) were from Biosynthan (Berlin, Germany): AP1, TFLLRN (PAR-1), AP2, SLIGKV (PAR-2), AP3, TFRGAP (PAR-3), and AP4, AYPGKF (PAR-4).
Cell culture
Human aortic SMC were isolated by the explant technique and cultured in Dulbecco's modified Eagle medium (Invitrogen, Karlsruhe, Germany) supplemented with 10% foetal calf serum as described. 22 
Human carotid artery plaques
Plaque samples were obtained after written informed consent from patients (age 64 -87 years) undergoing carotid endarterectomy and processed further anonymously. The study was approved by the Ethics Committee of the University Düsseldorf.
Semi-quantitative RT-PCR and real-time PCR
RNA isolation, semi-quantitative, and quantitative RT-PCR were performed as described. 23 Primer pairs for SPHK-1 were: forward, 5 ′ -ACCC ATGAACCTGCTGT CTC-3 ′ , reverse, 5 ′ -ACACACCTTTCCCATCC TTG-3 ′ (569 bp fragment, 608C annealing temperature). Quantitative PCR was performed on a Real-Time PCR System 7300 (Applied Biosystems, Darmstadt, Germany). TaqManw gene expression assays (Applied Biosystems) Hs00184211 (SPHK-1) and Hs99999905 (internal GAPDH control) were used according to the manufacturer's instructions.
Western blotting
Western blotting was performed with monoclonal antibodies against SPHK1 (clone 1D6) and FX/FXa (ab61361) on 10% polyacrylamide -SDS gels as previously described. 24 Equal protein loading was confirmed by reprobing with antibodies to b-actin (mouse monoclonal antibody from Sigma) after stripping (0.2N NaOH). 25 2.7 High-pressure liquid chromatography and thin layer chromatography S1P was determined either by high-pressure liquid chromatography (HPLC) as described previously 26 or by thin layer chromatography (TLC).
Extraction of sphingosine-1-phosphate
[ 3 H]-labelled lipid samples were resolved on silica gel 60 plates (MachereyNagel GmbH, Düren, Germany) for 1 h in dichloromethane:acetone (20:1) followed by a second run in butanol:acetic acid:water (3:1:1). Signals were visualized on autoradiography films, unlabelled lipid samples by charring reagent as described by others. 27 
In-cell western assay
Expression of SPHK1 protein was determined by the in-cell western assay 28 technique (LI-COR Biosciences, Bad Homburg, Germany) using infrared-labelled secondary antibodies according to the manufacturer's protocol. SMC in 96-well plates were serum-deprived for 48 h prior to stimulation. Cells were fixed with 4% (v/v) paraformaldehyde in PBS for 20 min and then permeabilized with 0.1% (v/v) Triton X-100 in PBS on a rocking platform. After blocking with 100 mL/well Odyssey blocking buffer (LI-COR), cells were incubated overnight at 48C with primary antibodies (anti-SPHK1, 1:100) in blocking buffer and then with secondary antibodies (IRDye 800CW Goat Anti-Mouse IgG, 1:600) for 1 h. For normalization to cell number, SMC were stained with the DNA dye DRAQ5 TM according to the manufacturer's protocol. Finally, cells were washed five times with 0.1% (v/v) Triton X-100 in PBS, followed by analysis on an Odyssey Reader at 700 and 800 nm.
Immunohistochemistry
FX/FXa, SPHK1, a-smooth muscle actin, smoothelin, and TF were visualized in paraffin-embedded sections of human carotid artery plaques. Images were taken with an AxioCam HRc camera and AxioVision 4.8 software (Zeiss) connected to a Zeiss Observer D1 microscope.
Rho A pulldown assay
Human SMC in 100 mm dishes were serum-starved for 48 h prior to stimulation with FXa. Activation of Rho A was determined in total cell lysates by a Rho-Rhotekin pulldown assay kit from Thermo Fisher Scientific according to the manufacturer's protocol.
Transfection with siRNA
Human SMC were transfected with 30 nmol/L siRNA (Dharmacon) directed against SPHK-1 or non-specific control siRNA by using RiboJuice TM (Merck) according to the manufacturer's instructions. Transfection was performed in serum-free media for 24 h. Media were exchanged and cells starved for additional 24 h prior to stimulation.
DNA synthesis and chemotaxis assays
DNA synthesis was determined by incorporation of [ cells were allowed to migrate into the scratch for 24-36 h. Experiments were performed in quadruplicate. Media were removed and the nuclei stained with Hoechst-33342 (Invitrogen). Cells migrated into the scratch were counted by a blinded observer and are shown as fold control.
Statistics
Statistical analysis was performed by non-parametric ANOVA (KruskalWallis test) and Dunn's multiple comparison post-hoc tests. P , 0.05 was considered significant.
Results

FXa induces expression of SPHK1 in human vascular SMC
Increased expression of SPHK1 mRNA was observed after incubation with FXa for 3 -6 h as determined by semi-quantitative reversetranscriptase PCR ( Figure 1A ). This was seen also seen in TaqManw realtime PCR analysis and at with lower FXa concentration (30 nmol/L, Figure 1B ). The effect of FXa on SPHK1 mRNA expression was mimicked by activating peptides specific for PAR-1 (AP1) and PAR-2 (AP2). Corresponding peptides with a scrambled sequence (see Supplementary material online, Figure S1A ) or activating-peptides for PAR-3 and -4 had no effect on SPHK1 mRNA (data not shown). The effect of FXa on SPHK1 protein was determined by western blotting. FXa increased SPHK1 protein within 6-24 h ( Figure 1C ). These effects were concentration-dependent at FXa concentrations ranging from 3 to 30 nmol/L ( Figure 1D ). In contrast, FXa did not affect mRNA expression of the SPHK2 isoform (see Supplementary material online, Figure S1B ) or of the S1P degrading enzymes S1P phosphatase-1 or S1P lyase in human SMC as seen from real-time PCR (see Supplementary material online, Figure S2 ).
FXa induces increased synthesis of S1P in human vascular SMC
Increased concentrations of endogenous S1P were determined by HPLC in lysates from human aortic SMC after incubation with FXa for 6 to 24 h (Figure 2A) . Similar effects were observed by TLC measurements on silica plates (see Supplementary material online, Figure S3A and 3B). To investigate changes in sphingosine and S1P turnover associated with enhanced SPHK activity by FXa, cells were incubated with [ 3 H]sphingosine to detect de novo synthesis and release of S1P from human SMC. After incubation with FXa (30 nmol/L) for 16 h, intracellular S1P synthesis and release to the conditioned media was increased by about two-fold when compared with unstimulated controls ( Figure 2B and C ).
FXa and SPHK1 are present in human atherosclerotic tissue
To determine whether FX and FXa are expressed in human atherosclerotic plaque and thus potentially affect SPHK1 expression in the vessel wall, human carotid artery plaques from eight different patients were immunostained for both FX/FXa and SPHK1. Positive immunostaining was observed in all samples with a monoclonal antibody which detects the zymogen FX as well as the cleaved and active form FXa. In consecutive tissue sections, positive immunostaining for FX/FXa was seen in areas of human plaques also positive for SPHK1 and for the SMC marker a-smooth muscle actin ( Figure 3A-C ) . The presence of both FX and FXa in plaque material was also validated by western blotting ( Figure 3D ). Co-localization of FXa and SPHK1 was also seen after fluorescence immunostaining ( Figure 3E-H ) . In further sections, double immunostaining for SPHK1 and a-smooth muscle actin was performed (see Supplementary material online, Figure S4 ). TF, which is required for activation of FXa, was detectable at the same sites (see Supplementary material online, Figure S4D ). Fluorescence immunostaining also suggest association of TF, FX/FXa, and SPHK1 with the specific SMC marker smoothelin 29 (see Supplementary material online, Figure   S5 ). In contrast, no immunostaining for FX/FXa was detectable in uninjured human saphenous vein segments, indicating that this molecule is not present in larger quantities within a healthy vessel wall (data not shown). In addition, expression of PAR-1 and PAR-2 receptors was demonstrated in the carotid artery plaques (see Supplementary material online, Figure S6 ).
FXa induces expression of SPHK1 via Rho-dependent signalling
Using the in-cell western technique from Li-Cor, the possible signalling pathways involved in FXa-mediated SPHK1 expression were investigated. Stimulation of SPHK1 expression by FXa was blocked by the Rho-associated kinase (ROCK) inhibitor Y27632 and the inhibitor of classical PKC isoforms GF109203X. In contrast, no effect on FXa-induced SPHK1 expression was seen with an inhibitor of the small GTPase Rac1 (NSC23766), the MAP kinase (MEK) inhibitor PD98059, or the highly selective PKA inhibitor myr-PKI ( Figure 4A ). In line with this observation, FXa activated the small GTPase RhoA ( Figure 4B ), of which ROCK is the downstream effector, 30 within 2-5 min. Translocation of SPHK1 from the cytoplasm to the cell membrane, as studied by immunocytochemistry (see Supplementary material online, Figure S7 ) and western blotting (data not shown) was not induced by FXa. In addition, siRNA for the classical PKC isoforms PKCa, PKCb, and PKCg in combination attenuated SPHK1 mRNA expression by FXa (see Supplementary material online, Figure S9B ), while either PKC siRNA alone was ineffective.
FXa-induced mitogenesis requires SPHK1 activity in human SMC
To evaluate the function of FXa-regulated SPHK1 expression in human SMC in more detail, FXa-stimulated DNA synthesis was measured. As shown previously, 4,5 FXa induced [ 3 H]thymidine incorporation, a measure for DNA synthesis. This was concentration-dependently suppressed by the inhibition of SPHK activity ( Figure 5A ), inhibition of ROCK and classical PKCs ( Figure 5B ). Involvement of any thrombin effects was excluded by the incubation of cells with hirudin. To further exclude possible non-specific inhibitor effects and to confirm the key role of SPHK1-derived S1P formation in FXa-induced mitogenesis, Figures S8 and 9A) . Mitogenesis of human SMC after incubation with FXa was significantly inhibited by SPHK-1 knockdown. Exogenous S1P did not prevent the effect of SPHK1 siRNA, suggesting that intracellular rather than extracellular S1P mediated the mitogenic effect ( Figure 5C ). To ensure that the lack of mitogenic response to exogenous S1P was not due to the absence of S1P receptors, expression of S1P receptors-1, -2, and -3 in the human SMC was confirmed by RT -PCR, and the biological activity of the S1P utilized here was ensured by the measurement of a concentrationdependent increase in endothelial cell migration (not shown). To further evaluate the mitogenic effects of intracellular S1P, we used caged S1P, a cell-permeable inactive formulation which is active FXa induces SPHK1 expression intracellularly by a UV light impulse. 31 Caged S1P evoked a concentration-dependent increase in DNA synthesis which was maximally at 1 mmol/L (see Supplementary material online, Figure S9C ).
FXa-induced migration requires SPHK1 activity in human SMC
Further studies addressed the functional role of SPHK-1 activity in FXa-induced SMC migration. In a wound-scratch assay, inhibition of SPHK activity with SKI or with the ROCK inhibitor Y27632 attenuated FXa-stimulated SMC migration ( Figure 6A and B) . A comparable effect was observed when SPHK1 expression was knocked down with siRNA ( Figure 6C) , collectively suggesting that SPHK1 activity is required for FXa-stimulated SMC migration.
Discussion
FXa is a key factor of thrombin formation in the blood-clotting cascade. In addition, numerous studies have emphasized its thrombinindependent role for cellular processes such as proliferation and migration of SMC. 2, 3, 5, 9 This includes its impact on atherosclerotic plaque development and vascular remodelling after vessel injury, as well as on other chronic inflammatory and proliferative diseases, including tissue fibrosis and cancer. 3 -5,9 S1P has also emerged as an important modulating factor in vascular inflammation during the progression of atherosclerosis, and has been connected to PAR-1 signalling. 32, 33 Therefore, the aim of our study was to identify a possible link between cellular FXa effects and the vascular S1P system. In human aortic and human saphenous vein (data not shown) SMC FXa induced transcription of SPHK-1 mRNA and its translation into protein (Figure 1 ). This effect was mimicked by the activation of PAR-1 and PAR-2, suggesting that FXa induces SPHK-1 expression through the activation of both receptors. The increased expression of SPHK-1 resulted in an enhanced intracellular synthesis of S1P (Figure 2) . The extracellular levels of newly synthesized S1P-determined by the incubation of FXa-stimulated cells with [ 3 H]sphingosine-were also increased, implying enhanced release of cellular S1P in addition to intracellular production. Although our data do not indicate regulated transcription of the SPHK2 isoform by FXa, they do also not exclude a possible effect on SPHK2 activity.
To determine whether the effects of FXa on SPHK-1 levels observed in vitro are relevant in vivo, we assessed whether FXa is present also in atherosclerotic plaque tissue. Using a monoclonal antibody which recognizes both FX and FXa, we found positive immunostaining in human carotid artery plaques. Western blotting indicated that both the inactive and the active form of the coagulation factor are present within plaque material. The presence of multiple bands ( Figure 3D ) may be due to degradation during sample processing. However, some non-specific signals cannot be fully excluded. In addition, positive signals were detected for smooth muscle actin and smoothelin, indicating smooth muscle cell association, and for TF, the initiator of FXa generation. 1 Smoothelin has been described as highly specific for SMC and is also present at the luminal side in atherosclerotic lesions. 29 Expression of SPHK1 in the same areas of the plaques suggested close localization of both proteins FXa and SPHK1 ( Figure 3 and see Supplementary material online, Figure S5 ). FXa may therefore regulate SPHK-1 expression in human plaque SMC. It should be noted that cultured SMC do not necessarily behave in a manner similar to SMC in atherosclerotic lesions and also divergent SMC subtypes within atherosclerotic plaques have been described. 34, 35 Thus, further mechanistic studies may address the functional interaction of FXa effects and the S1P pathway in vivo. Atherosclerotic plaque materials are known to be highly thrombogenic. Thus far, this has been attributed to increased TF expression by secretory SMC within the atherosclerotically altered vessel wall. 36, 37 The data presented here suggest that not only is TF expression increased in plaques, but also that FX and even FXa may already be present within atherosclerotic tissue. Intra-plaque FXa might alter plaque composition and could expedite or aggravate thrombin generation and platelet activation at sites of plaque rupture.
Further experiments addressed the signalling pathways which regulate increased S1P expression by FXa. Using various specific inhibitors of PAR-regulated signalling pathways, we identified the Rho-ROCK pathway as being involved in FXa-induced SPHK1 regulation. In line with these observations, FXa was shown to rapidly induce the activation of Rho A ( Figure 4B ). In addition, PKC, which has been reported to be required for the activation of Rho/ROCK in vascular SMC, 38 may play a role in SPHK1 regulation since inhibition of classical PKC isoforms and siRNA against PKCabg inhibited the stimulatory effects of FXa on SPHK-1 expression. In contrast, Rac-1, MEK, and PKA signalling were not found to contribute to SPHK1 regulation, nor did pertussis toxin as an inhibitor of predominantly Ga i -coupled signalling 39 inhibit SPHK1 transcription (data not shown).
Further experiments explored the pathophysiological role of increased SPHK1 expression. We were particularly interested in the possible impact of FXa-induced S1P synthesis on mitogenesis and migration of human SMC. The precise function of S1P in these processes, specifically the relative contribution of intra-vs. extracellular S1P, has been controversially discussed. Early studies found that increased intracellular S1P levels enhanced cell proliferation, suggesting a growth promoting role for S1P. 19 Later studies suggested that the intracellular location of S1P, e.g. derived from the respective intracellular localization of SPHK1, is crucial to determine its function. 40 Extracellular S1P has been shown to directly induce SMC migration, however, it may interfere with or inhibit PDGF-induced chemotaxis. 41 In addition, the different S1P receptors appear to have distinct functions. While extracellular S1P elicits a net migratory effect in SMC, the S1P 2 receptor attenuates this response and may function as a negative regulator of chemotaxis to counterbalance the response, e.g. to vascular injury. 42 Another recent study found that extracellular S1P induced directional migration, while intracellular S1P was required for increased cell mobility. 43 In our study, inhibition of SPHK1 activity with SKI attenuated the mitogenic and migratory response of human SMC to FXa. A similar suppression was seen with inhibitors of ROCK and PKC, which reduced SPHK1 expression. This is likely to involve direct effects of these inhibitors on DNA synthesis and migration of SMC. 38 However, comparable inhibitory effects on FXa-induced SMC mitogenesis and migration were seen when the expression of SPHK1 was knocked down by siRNA confirming the specificity of the SKI effect. Application of extracellular S1P FXa induces SPHK1 expression was, however, not sufficient to counteract the effect of SPHK1 knockdown. In addition, co-incubation with the direct thrombin inhibitor hirudin excluded a contribution of SMC-derived prothrombin in vitro.
These observations point to an important function of intracellular S1P as mediator for cellular FXa responses and is supported by the observation that increasing intracellular levels with caged S1P also elicits mitogenesis. This is in agreement with the earlier studies characterizing S1P as an intracellular second messenger regulating cell proliferation, 19 calcium homeostasis, 20 and suppression of apoptosis. 15, 21 Interestingly, FXa not only induced intracellular S1P levels, but also appeared to enhance the levels of extracellular S1P. The physiological role of FXa-induced S1P release from SMC needs to be addressed in future studies. In summary, our study describes for the first time that FXa enhances the generation of S1P in human vascular SMC via increased expression of SPHK-1. Further, we demonstrate the presence of FX and FXa in co-localization with SPHK-1 in human carotid artery plaques. In vitro, FXa directly induces SMC mitogenesis and migration. This is attenuated by suppressing SPHK-1 activity or expression, indicating a role for S1P in FXa-mediated SMC proliferation and chemotaxis. Taken together, these data suggest an important modulating effect of FXa not only at sites of plaque rupture, but also within atherosclerotic plaque tissue. This may be of clinical relevance for the use of novel direct FXa inhibitors in patients with atherosclerosis and requires evaluation in future studies.
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